Status:

RECRUITING

Optoacoustic Detection of Inflammation Using MSOT Device

Lead Sponsor:

University of Oklahoma

Conditions:

Graft Vs Host Disease

Colitis

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to evaluate the safety and potential of a new experimental imaging instrument called multispectral optoacoustic tomography (MSOT) to detect inflammation in patients with c...

Detailed Description

This is a single arm, 3-cohort study that is designed to provide safety information regarding the use of the Acuity MSOT device in the clinical setting, and the ability of MSOT imaging data to correla...

Eligibility Criteria

Inclusion

  • Patients documented clinical/pathologic 1) acute or chronic colon or skin GVHD, 2) Crohn's disease, or 3) colitis
  • Have acceptable hematologic status \[total hemoglobin (tHb) ≥ 7.0 mg/dL\]
  • Patients ≥ 18 yrs of age
  • Willing to comply with study procedures and be available for the duration of the study
  • Patient has ability to understand and the willingness to provide a signed and dated IRB-approved informed consent document.

Exclusion

  • Patients with a tattoo over the area of inflammation
  • Pregnant patients are not eligible for this trial. Eligible patients (if applicable) will be required to document the date of the first day of their last menstrual cycle, and provide a negative pregnancy test if sexually active and of childbearing potential
  • Patients who are breastfeeding
  • Any open wound (skin ulcerations or infections) at or near the site of imaging that would preclude MSOT imaging.
  • Any febrile illness that precludes or delays participation preoperatively

Key Trial Info

Start Date :

May 31 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2028

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT05333978

Start Date

May 31 2022

End Date

May 1 2028

Last Update

January 8 2026

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Oklahoma Health Sciences Center, Stephenson Cancer Center

Oklahoma City, Oklahoma, United States, 73014